EyeGene Statistics

Total Valuation

EyeGene has a market cap or net worth of KRW 83.66 billion. The enterprise value is 55.89 billion.

Market Cap	83.66B
Enterprise Value	55.89B

Important Dates

The next estimated earnings date is Wednesday, August 13, 2025.

Earnings Date	Aug 13, 2025
Ex-Dividend Date	n/a

Share Statistics

EyeGene has 27.03 million shares outstanding. The number of shares has increased by 17.63% in one year.

Current Share Class	27.03M
Shares Outstanding	27.03M
Shares Change (YoY)	+17.63%
Shares Change (QoQ)	+0.42%
Owned by Insiders (%)	6.59%
Owned by Institutions (%)	0.07%
Float	19.44M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	22.92
PB Ratio	1.69
P/TBV Ratio	1.93
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-4.66
EV / Sales	15.31
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-6.72

Financial Position

The company has a current ratio of 3.47, with a Debt / Equity ratio of 0.05.

Current Ratio	3.47
Quick Ratio	3.38
Debt / Equity	0.05
Debt / EBITDA	n/a
Debt / FCF	-0.30
Interest Coverage	-17.42

Financial Efficiency

Return on equity (ROE) is -23.02% and return on invested capital (ROIC) is -13.28%.

Return on Equity (ROE)	-23.02%
Return on Assets (ROA)	-11.29%
Return on Invested Capital (ROIC)	-13.28%
Return on Capital Employed (ROCE)	-22.89%
Revenue Per Employee	74.49M
Profits Per Employee	-244.84M
Employee Count	49
Asset Turnover	0.05
Inventory Turnover	7.78

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +10.00% in the last 52 weeks. The beta is 1.49, so EyeGene's price volatility has been higher than the market average.

Beta (5Y)	1.49
52-Week Price Change	+10.00%
50-Day Moving Average	3,263.80
200-Day Moving Average	2,959.33
Relative Strength Index (RSI)	43.12
Average Volume (20 Days)	62,815

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, EyeGene had revenue of KRW 3.65 billion and -12.00 billion in losses. Loss per share was -443.42.

Revenue	3.65B
Gross Profit	1.15B
Operating Income	-12.18B
Pretax Income	-12.53B
Net Income	-12.00B
EBITDA	-9.78B
EBIT	-12.18B
Loss Per Share	-443.42

Full Income Statement

Balance Sheet

The company has 32.35 billion in cash and 2.53 billion in debt, giving a net cash position of 29.82 billion or 1,103.28 per share.

Cash & Cash Equivalents	32.35B
Total Debt	2.53B
Net Cash	29.82B
Net Cash Per Share	1,103.28
Equity (Book Value)	49.55B
Book Value Per Share	1,757.34
Working Capital	24.41B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -6.80 billion and capital expenditures -1.51 billion, giving a free cash flow of -8.31 billion.

Operating Cash Flow	-6.80B
Capital Expenditures	-1.51B
Free Cash Flow	-8.31B
FCF Per Share	-307.57

Full Cash Flow Statement

Margins

Gross Margin	31.47%
Operating Margin	-333.62%
Pretax Margin	-343.34%
Profit Margin	n/a
EBITDA Margin	-268.00%
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

EyeGene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-17.63%
Shareholder Yield	n/a
Earnings Yield	-14.34%
FCF Yield	-9.94%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on June 28, 2021. It was a forward split with a ratio of 1.2.

Last Split Date	Jun 28, 2021
Split Type	Forward
Split Ratio	1.2

Scores

EyeGene has an Altman Z-Score of -0.24 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.24
Piotroski F-Score	2